Department of Medicine, Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, Canada.
J Clin Gastroenterol. 2011 Nov;45 Suppl:S139-44. doi: 10.1097/MCG.0b013e31822103f7.
Crohn's disease, ulcerative colitis, and pouchitis after ileal pouch anal anastomosis in ulcerative colitis patients are often refractory to standard therapy. Over the last decade, the rational to use probiotics and its beneficial efficacy in the treatment of chronic inflammatory bowel disease (IBD) is increasingly under scrutiny. Although it has become clear that intestinal epithelial-mucosal immune interactions and enteric bacteria play a critical role in the development of IBD, the substantial clinical efficacy of probiotics in these disorders is less evident. This review outlines the clinical studies regarding probiotics before October 2007. These studies formed the foundation of probiotic clinical trials in IBD, but they also indicated the need of larger and better-controlled studies than the past experimental approaches. Furthermore, this review also examines in-depth the probiotic clinical trials published between 2007 and December 2010, providing new insights into the role of probiotics for inducing and maintaining remission of IBD, and highlighting some of the breakthroughs, especially regarding induction of remission for ulcerative colitis.
克罗恩病、溃疡性结肠炎和溃疡性结肠炎患者的回肠贮袋肛门吻合术后的贮袋炎常对标准治疗无效。在过去十年中，益生菌的合理应用及其在治疗慢性炎症性肠病（IBD）中的有益疗效受到越来越多的关注。尽管已经清楚肠道上皮-黏膜免疫相互作用和肠道细菌在 IBD 的发展中起关键作用，但益生菌在这些疾病中的显著临床疗效却不明显。本综述概述了 2007 年 10 月之前关于益生菌的临床研究。这些研究为 IBD 的益生菌临床试验奠定了基础，但也表明需要进行比过去的实验方法更大规模和更好控制的研究。此外，本综述还深入研究了 2007 年至 2010 年 12 月期间发表的益生菌临床试验，为益生菌在诱导和维持 IBD 缓解方面的作用提供了新的见解，并强调了一些突破，特别是在诱导溃疡性结肠炎缓解方面。
